Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 7:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Obesity, Overweight
Interventions
Bimagrumab, Tirzepatide, Bimagrumab Placebo, Tirzepatide Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
12
States / cities
Anniston, Alabama • Birmingham, Alabama • Walnut Creek, California + 9 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia

NCT01669174
Conditions
Chronic Obstructive Pulmonary Disease (COPD) With Cachexia
Interventions
Placebo, BYM338
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 80 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
5
States / cities
Torrance, California • Savannah, Georgia • Normal, Illinois + 2 more
Conditions
Cachexia
Interventions
BYM338 active drug, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Tucson, Arizona • Tampa, Florida • Chicago, Illinois + 3 more
Conditions
Skeletal Muscle
Interventions
BYM338, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
65 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Miami, Florida + 1 more
Conditions
Obesity
Interventions
Bimagrumab, Tirzepatide, Calcium/Vitamin D, Lifestyle and nutrition counseling
Drug · Dietary Supplement · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Phase 2 Interventional Results available

Dose Range Finding Study of Bimagrumab in Sarcopenia

NCT02333331
Conditions
Sarcopenia
Interventions
bimagrumab, placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
70 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
17
States / cities
Little Rock, Arkansas • Cypress, California • La Jolla, California + 14 more
Conditions
Muscle Wasting (Atrophy) After Hip Fracture Surgery
Interventions
bimagrumab, placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
6
States / cities
Phoenix, Arizona • El Cajon, California • Denver, Colorado + 3 more
Conditions
Obesity, Obese, Overweight or Obesity
Interventions
Bimagrumab, Semaglutide, Placebo
Biological · Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Anniston, Alabama • Cullman, Alabama • Hialeah, Florida + 7 more
Conditions
Sarcopenia
Interventions
bimagrumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
70 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Miami Lakes, Florida • Gainesville, Georgia • Spartanburg, South Carolina + 2 more
Conditions
Sporadic Inclusion Body Myositis
Interventions
BYM338/bimagrumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
36 Years to 85 Years
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
12
States / cities
Phoenix, Arizona • Orange, California • Sacramento, California + 8 more
Conditions
Sporadic Inclusion Body Myositis
Interventions
Bimagrumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
36 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Phoenix, Arizona • Orange, California • Sacramento, California + 8 more
Conditions
Sporadic Inclusion Body Myositis
Interventions
BYM338, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Scottsdale, Arizona • Kansas City, Kansas • Boston, Massachusetts
Conditions
Obesity, Overweight
Interventions
Bimagrumab, Tirzepatide, Bimagrumab Placebo, Tirzepatide Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
25
States / cities
Yuma, Arizona • Lake Forest, California • Long Beach, California + 22 more
Conditions
Diabetes Mellitus, Type 2
Interventions
BYM338 10 mg/kg, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Anaheim, California • Miami, Florida • Miami Lakes, Florida + 4 more